Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Study identification

• EU PAS number:
  EUPAS1000000551
• Study ID:
  1000000551
• Official title and acronym:
  Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
• DARWIN EU® study:
  No
• Study countries:
  Australia

  Korea, Republic of

  United States
• Study description:
  This study aims to compare ticagrelor and prasugrel, P2Y12 antiplatelet agents commonly used in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). ; Given ongoing uncertainty from prior trials, mixed guideline recommendations, and the limitations of previous observational research, additional rigorous real-world evidence is needed to clarify optimal treatment strategies for ACS. ; By conducting a direct, head-to-head comparison, this research will provide valuable insights into their comparative effectiveness and safety.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Yonsei University

UMass Chan Medical School
UT Southwestern
University of New Mexico
VUMC
Penn State Health
UNSW Sydney

Networks

Observational Health Data Sciences and Informatics (OHDSI) Network

Study timelines

Date when funding contract was signed

Planned: 01/03/2025

Actual: 01/03/2025

Study start date

Planned: 14/04/2025

Actual: 14/04/2025

Data analysis start date

Planned: 14/04/2025

Actual: 14/04/2025

Date of final study report

Planned: 31/12/2025

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable